-

EOSE Investor Alert: Eos Energy Enterprises, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Automated Production Claims: Levi & Korsinsky

Time-Sensitive: Allegations Focus on Automated Bipolar Production Quality Representations

"Investors deserve transparency about material risks that could affect their investments, particularly when a company's public statements paint a picture of operational progress that allegedly diverges from manufacturing reality," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Eos Energy Enterprises, Inc. (NASDAQ: EOSE) of a pending securities class action. Class Period: November 5, 2025 through February 26, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

EOSE shares lost $4.39 per share, a 39.4% single-day decline, closing at $6.74 on February 26, 2026, after the Company disclosed that its automated bipolar production failed to hit quality targets, driving rework and lost revenue. The deadline to apply for lead plaintiff appointment is May 5, 2026.

The Alleged Automated Bipolar Quality Deficiency

The lawsuit asserts that throughout the Class Period, management promoted a narrative of smooth automation progress at its Turtle Creek manufacturing facility. Public statements highlighted that 88% of bipolar lines were in commercial production and that subassembly automation was advancing as planned. What shareholders were not told, the action claims, was that automated bipolar production was failing to meet quality targets, generating significant rework that consumed production capacity and destroyed revenue.

Zinc Battery Manufacturing Quality Challenges in Automated Environments

The securities action focuses on how quality failures in an automated production environment compound differently than in manual or semi-automated settings:

  • Automated bipolar production lines that cannot hit quality targets generate defective output at scale, multiplying rework costs with every hour of operation
  • Rework from quality failures allegedly consumed production time that had been counted toward revenue guidance of $150 million to $160 million
  • As alleged, tightened material specifications and improved tooling were not implemented until after quality problems had already eroded revenue
  • Laser detection systems for process variation control were added only after the damage, suggesting the original quality monitoring was allegedly inadequate
  • The gap between the Company's claimed automation progress and actual quality performance allegedly widened throughout Q4 2025
  • Actual full year revenue of $114.2 million fell $35.8 million to $45.8 million short of guidance, with quality-driven rework cited as a contributing factor

Why Automated Production Quality Allegedly Matters to Investors

The complaint contends that Eos Energy's investment thesis rested on its ability to scale zinc-based battery production through automation. When management represented that its first fully automated manufacturing line was installed and in commercial production, investors reasonably understood that quality benchmarks were being met. The action claims this representation was materially misleading because automated bipolar production was not hitting quality targets, a fact that directly undermined the revenue ramp that justified the Company's guidance and stock price.

Speak with an attorney about recovering damages or call (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:EOSE

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

SHAK Investor Alert: Levi & Korsinsky Investigates Shake Shack (SHAK) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shake Shack (NYSE: SHAK) lost approximately 9-10% of its value today after the company cut FY 2026 restaurant-level profit margin guidance from 23-23.5% to 22-23% and trimmed quarterly guidance from 24-24.5% to only 22-23%. Shareholders who lost money on SHAK are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.On May 7, 2026 -- just 26 days before today'...

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum’s June 1, 2026 Form 8-K, which...

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submi...
Back to Newsroom